How to safely taper biologic or targeted-synthetic drugs in inflammatory arthritis
PROSPECT: PRedicting disease-mOdifying anti-rheumatic drug doSe reduction response in rheumatoid and Psoriatic arthritis with EConomic evaluaTion
We are looking for people with well-controlled Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) on biologic or targeted-synthetic drugs. The study aims to test new approaches of safely reducing and stopping these medications, and through biobank samples for lab analysis you can help us predict these for the future.
The duration of this randomized clinical trial is 24 months with a maximum of 8 clinic visits. There are study sites in Sydney, Melbourne, Brisbane, Adelaide, Perth and Canberra. Travel expenses associated with the visits will be reimbursed, in the form of a gift card with $15 each visit.
Eligibility
You may be eligible to participate in this study if you:
- are aged 18 years or over
- first started any biologic or targeted synthetic Disease Modifying Antirheumatic Drugs (b/tsDMARDs) at least 2 years ago
- are in remission or low disease activity and have been stable on DMARD for at least 6 months, and
- if you are on oral corticosteroids, the dose is stable and less than 5mg prednisone daily equivalent
- are not on an ineligible DMARD medication (e.g. rituximab, ustekinumab, guselkumab)
- have not had any intravenous (into the blood) or intra-articular (into the joint) corticosteroid injections in the last 6 months
- don’t have concurrent medical conditions that are likely to impact your safety or interfere with the evaluation of the study outcome
- are not pregnant
- have not had an investigational new drug within the last 12 weeks
How to participate
If you are interested in assisting with this important and exciting area of research, please discuss it with your rheumatologist to confirm your eligibility and contact prospect.trial@sydney.edu.au to arrange the next enrolment step.
Or
Call our research coordinator, Jie Yi, at 02 9463 1758 (9am – 5pm, Mon to Fri)